



Progenics Pharmaceuticals Inc, Tarrytown, NY 10591, USA.- Curr Opin HIV AIDS. 2009 Mar;4(2):104-11. ([DOI Direct Link](#))

- [A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.](#)  
*PURPOSE: Prostate-specific membrane antigen (PSMA) is an attractive target...*7th September, 2007  
Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.- Clin Cancer Res. 2007 Jul 1;13(13):3999-4008. ([DOI Direct Link](#))
- [Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers.](#)  
*HIV type 1 (HIV-1) envelope is a noncovalent trimer of gp120-gp41...*29th August, 2007  
Progenics Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.- AIDS Res Hum Retroviruses. 2007 Jun;23(6):817-28. ([DOI Direct Link](#))
- [Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.](#)  
*The chemokine receptor CCR5 provides a portal of entry for human...*9th December, 2006  
Progenics Pharmaceuticals, Inc, Tarrytown, NY 10591, USA.- Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96. ([DOI Direct Link](#))
- [Resistance to HIV-1 entry inhibitors.](#)  
*Resistance-testing technology has been incorporated into the standard of...*16th April, 2004  
Progenics Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY- Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94.
- [Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.](#)  
*Viral entry inhibitors represent an emerging mode of therapy for human...*12th March, 2004  
Mount Sinai Medical Center, New York, New York 10029. Progenics- Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.
- [The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.](#)  
*Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane...*6th January, 2004  
Progenics Pharmaceuticals, Inc., and PSMA Development Company, LLC,- Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12590-5. ([DOI Direct Link](#))
- [L-SIGN \(CD 209L\) is a liver-specific capture receptor for hepatitis C virus.](#)  
*Hepatitis C virus (HCV) infects nearly 3% of the population of the world...*18th June, 2003  
Progenics Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown,- Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4498-503. Epub 2003 Apr 3. ([DOI Direct Link](#))
- [Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.](#)  
*Inhibitors of human immunodeficiency virus type 1 attachment...*15th March, 2003  
Progenics Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.- J Virol. 2003 Feb;77(4):2762-7.
- [HIV entry inhibitors in clinical development.](#)  
*Despite recent advances, present therapies for human immunodeficiency...*15th March, 2003  
Progenics Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.- Curr Opin Pharmacol. 2002 Oct;2(5):523-8.

## Press Releases on Progenics Pharmaceuticals:

<a href="#">Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients</a>	23rd November, 2009	Cumberland Pharmaceuticals Inc.	NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of
<a href="#">Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009</a>	23rd November, 2009	Lexicon Pharmaceuticals, Inc.	THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with
<a href="#">Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders</a>	23rd November, 2009	Isis Pharmaceuticals, Inc.	CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the
<a href="#">Oceanside Pharmaceuticals Announces Launch of Librax(R) AG</a>	23rd November, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide
<a href="#">Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference</a>	23rd November, 2009	Sagent Pharmaceuticals, Inc.	SCHAUMBURG, Ill., Nov. 23 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon,

## BioNews Results for Progenics Pharmaceuticals



- [CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results](#)  
*Pharmacy Choice: Nov 10 2009 6:08AM Matching: progenics pharmaceuticals*
- [Progenics Announces Third Quarter 2009 Financial Results](#)  
*Therapeutics Daily: Nov 10 2009 2:23AM Matching: progenics pharmaceuticals*
- [CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results](#)

- Freshnews.com: Nov 9 2009 3:58PM Matching: progenics pharmaceuticals*
- [CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results](#)
- Yahoo! Canada: Nov 9 2009 2:44PM Matching: progenics pharmaceuticals*
- [Progenics Announces Third Quarter 2009 Financial Results](#)
- Pharma Live: Nov 9 2009 7:26PM Matching: progenics pharmaceuticals*
- [Progenics Announces Third Quarter 2009 Financial Results](#)
- Individual.com: Nov 9 2009 2:18PM Matching: progenics pharmaceuticals*
- [Progenics Pharmaceuticals Inc-Financial Company Report - research report released](#)
- PR inside: Nov 2 2009 2:50PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Interest!ALERT: Oct 29 2009 3:49PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Individual.com: Oct 29 2009 3:55PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Individual.com: Oct 29 2009 3:54PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- SmartBrief: Oct 29 2009 6:18PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Street Insider: Oct 29 2009 1:58PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- PR Newswire via Yahoo!: Oct 29 2009 2:07PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Yahoo! Canada: Oct 29 2009 1:52PM Matching: progenics pharmaceuticals*
- [BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals](#)
- Therapeutics Daily: Oct 29 2009 4:55PM Matching: progenics pharmaceuticals*

## Progenics Pharmaceuticals Patents:



- 7592014- [Stabilized viral envelope proteins and uses thereof](#)
- 6710173- [Stabilized viral envelope proteins and uses thereof](#)
- 6548636- [Sulfated CCR5 peptides for HIV-1 infection](#)
- 6451313- [CD4-gamma2 and CD4-IGG2 chimeras](#)
- 6344545- [Method for preventing HIV-1 infection of CD4+ cells](#)
- 6342586- [Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof](#)
- 6261763- [Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion](#)
- 6187748- [Uses of CD4-gamma2 and CD4-IgG2 chimeras](#)
- 6177549- [Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof](#)
- 6107019- [Method for preventing HIV-1 infection of CD4.sup.+ cells](#)
- 6083478- [Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof](#)
- 6034223- [Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof](#)

- [thereof](#)
- 5886163- [HIV-1 antigens, antibody compositions related thereto, and therapeutic and prophylactic uses thereof](#)
- 5869624- [HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof](#)
- 6737267- [Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof](#)
- 6908734- [Sulfated CCR5 peptides for HIV-1 infection](#)
- 7563899- [\(S\)-N-methylnaltrexone](#)
- 7479553- [Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 \(HIV-1\) gp140 envelope glycoproteins](#)
- 7446177- [Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection](#)
- 7361503- [Sequences encoding hepatitis C virus glycoproteins](#)
- 7345153- [Compounds capable of inhibiting HIV-1 infection](#)
- 7138119- [Compositions and methods for inhibition of HIV-1 infection](#)
- 7122185- [Anti-CCR5 antibody](#)
- 7118859- [Methods for inhibiting HIV-1 infection](#)
- 7070991- [Cells expressing a CD4-IgG2 chimeric heterotetramer](#)
- 7060273- [Methods for inhibiting HIV-1 infection](#)
- 7022324- [Stabilized viral envelope proteins and uses thereof](#)
- 7022323- [Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection](#)
- 6972126- [Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same](#)
- 5817767- [Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

